Interaksi Fenofibrat dan Gemfibrozil

Fenofibrat dan Gemfibrozil: kedua label peresepan menguraikan interaksi yang biasanya memerlukan pemantauan, perubahan dosis, atau pemberian jarak antardosis.

Moderat

Biasanya dapat dikelola dengan pemantauan atau perubahan dosis. Beri tahu apoteker Anda bahwa Anda menggunakan keduanya.

Apa kata label FDA

Dari label Gemfibrozil (Lopid) · berlaku sejak 2026-05-21

Moderat

A comparative carcinogenicity study was also done in rats comparing three drugs in this class: fenofibrate (10 and 60 mg/kg; 0.3 and 1.6 times the human dose, respectively), clofibrate (400 mg/kg; 1.6 times the human dose), and gemfibrozil (250 mg/kg; 1.7 times the human dose).

Peringatanmenyebut FenofibratLihat label di DailyMed
Moderat

Pancreatic acinar adenomas were increased in males and females on fenofibrate; hepatocellular carcinoma and pancreatic acinar adenomas were increased in males and hepatic neoplastic nodules in females treated with clofibrate; hepatic neoplastic nodules were increased in males and females treated with clofibrate; hepatic neoplastic nodules were increased in males…

Peringatanmenyebut FenofibratLihat label di DailyMed

Dari label Fenofibrat (Fenofibrate) · berlaku sejak 2026-05-12

Minor

Because of chemical, pharmacological, and clinical similarities between fenofibrates, including fenofibrate; pemafibrate; clofibrate; and gemfibrozil; the findings in 5 large randomized, placebo-controlled clinical trials with these other fibrate drugs may also apply to fenofibrate capsules.

Peringatan dan perhatianmenyebut GemfibrozilLihat label di DailyMed
Minor

Subjects received either placebo or gemfibrozil for 5 years, with a 3.5-year open extension afterward.

Peringatan dan perhatianmenyebut GemfibrozilLihat label di DailyMed
Minor

Total mortality was numerically but not statistically higher in the gemfibrozil randomization group versus placebo [95% confidence interval (CI) of the hazard ratio (HR) 0.91 to 1.64] .

Peringatan dan perhatianmenyebut GemfibrozilLihat label di DailyMed
Minor

A secondary prevention component of the Helsinki Heart Study treated middle-aged men with gemfibrozil or placebo for 5 years.

Peringatan dan perhatianmenyebut GemfibrozilLihat label di DailyMed

Menggunakan lebih dari dua obat ini? Interaksi saling bertumpuk. Periksa seluruh daftar Anda sekaligus; daftar itu tetap berada di peramban Anda.

Buka di pemeriksa

Bukan nasihat medis. Interaction Checker mengutip teks label FDA dan lembar fakta NIH. Penting atau tidaknya suatu interaksi bagi Anda bergantung pada dosis, waktu penggunaan, fungsi ginjal dan hati, serta kondisi lain. Pastikan dengan apoteker atau dokter yang meresepkan.